MICHAEL E RYTTING to Antineoplastic Agents
This is a "connection" page, showing publications MICHAEL E RYTTING has written about Antineoplastic Agents.
Connection Strength
0.605
-
Asparaginase in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S14-7.
Score: 0.097
-
Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther. 2010 May; 10(5):833-9.
Score: 0.072
-
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma. 2004 Aug; 45(8):1623-6.
Score: 0.048
-
Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives. Paediatr Drugs. 2021 Sep; 23(5):457-463.
Score: 0.039
-
Acute myeloid leukaemia. Lancet. 2018 08 18; 392(10147):593-606.
Score: 0.032
-
Phase-contrast cerebrospinal fluid flow magnetic resonance imaging in qualitative evaluation of patency of CSF flow pathways prior to infusion of chemotherapeutic and other agents into the fourth ventricle. Childs Nerv Syst. 2018 03; 34(3):481-486.
Score: 0.030
-
Questions on asparaginase-associated pancreatitis. Lancet Oncol. 2017 09; 18(9):1148-1149.
Score: 0.030
-
Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403.
Score: 0.029
-
Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am. 1996 Apr; 10(2):365-76.
Score: 0.027
-
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
Score: 0.026
-
Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. J Neurooncol. 2015 Oct; 125(1):133-41.
Score: 0.026
-
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6.
Score: 0.025
-
Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012 Feb; 35(1):51-7.
Score: 0.020
-
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.
Score: 0.020
-
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol. 2011 Apr; 67(4):875-90.
Score: 0.018
-
Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. 2005 Mar; 27(3):166-8.
Score: 0.013
-
Pediatric myelodysplastic syndromes. Curr Hematol Rep. 2004 May; 3(3):173-7.
Score: 0.012
-
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9.
Score: 0.011
-
Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999 Jul 01; 86(1):126-34.
Score: 0.008
-
Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. Anticancer Drugs. 1999 Jul; 10(6):519-24.
Score: 0.008
-
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444.
Score: 0.007
-
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009 Sep 10; 27(26):4392-7.
Score: 0.004